Table 7 Small cell lung cancer: response to newer agents [6, 34–38]
AgentResponse rate (%)
Paclitaxel34–41
Irinotecan47#
Topotecan39
Docetaxel28#
Gemcitabine26
Vinorelbine12.5#
Bendamustine72.7% first-line in combination with carboplatin
Amrubicin21.3# (refractory patients), 44# (sensitive patients)

  • #: previously treated patients only.